Antisense approaches for inhibiting respiratory syncytial virus

Bibliography

• COLLINS CL, POLLARD AJ: Respiratory syncytial virus infections in children and adults. J. Infect. (2002) 45(1):10–17.
   PubMed Web of Science ®Google Scholar
• HALL CB: Nosocomial respiratory syncytial virus infections: the 'Cold War' has not ended. Clin. Infect. Dis. (2000) 31(2):590–596.
   PubMed Web of Science ®Google Scholar
• GLEZEN WP, TABER LH, FRANK AL, KASEL JA: Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child (1986) 140(6):543–546.
   PubMedGoogle Scholar
• WYDE PR: Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res. (1998) 39(2):63–79.
   PubMed Web of Science ®Google Scholar
• FALSEY AR, WALSH EE: Respiratory syncytial virus infection in adults. Clin. Microbiol Rev. (2000) 13(3):371–384.
   PubMed Web of Science ®Google Scholar
• THOMPSON WW, SHAY DK, WEINTRAUB E et al.: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 289(2):179–186.
   PubMed Web of Science ®Google Scholar
• COLLINS PL, CHANOCK RH, MCINTOSH K: Respiratory syncytial virus. In: Field's Virology. Fields BN, Knipe DM (Eds), Lippincott-Raven, Philadelphia, PA, USA (1996):1313–1351. Excellent review on the molecular biology of RSV.
   Google Scholar
• SHAY DK, HOLMAN RC, ROOSEVELT GE, CLARKE MJ, ANDERSON LJ: Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997.1 Infect. Dis. (2001) 183(1):16–22.
   Google Scholar
• ZAMBON MC, STOCKTON JD, CLEWLEY JP, FLEMING DM: Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet (2001) 358(9291):1410–1416.
   PubMed Web of Science ®Google Scholar
• RUEF C: Respiratory syncytial virus infections-an underdiagnosed entity? Infection (2002) 30(4):185.
   PubMed Web of Science ®Google Scholar
• HAN LL, ALEXANDER JP, ANDERSON LJ: Respiratory syncytialvirus pneumonia among the elderly: an assessment of disease burden. J. Infect. Dis. (1999) 179(1):25–30.
   PubMed Web of Science ®Google Scholar
• MAGGON K, BARIK S: New drugs and treatment for respiratory syncytial virus. Rev. Med. Virol. (2004) 14(3):149–168. Recent comprehensive review on drugs and vaccines against RSV in early and late stage development.
   Google Scholar
• PARAMORE LC, CIURYLA V, CIESLA G, LIU L: Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics (2004) 22(5):275–284.
   PubMed Web of Science ®Google Scholar
• MARTINEZ FD: Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr. Infect. Dis. (2003) 22(2 Suppl.):576–582.
   Google Scholar
• SIGURS N: Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am. J. Respir. Crit. Care Med. (2001) 163(3 Pt 2):52–56.
   Google Scholar
• HALL CB, LONG CE, SCHNABEL KC: Respiratory syncytial virus infections in previously healthy working adults. Clin. Infect. Dis. (2001) 33(0:792–796.
   PubMedGoogle Scholar
• HASHEM M, HALL CB: Respiratory syncytial virus in healthy adults: the cost of a cold. J. Clin. Wrol. (2003) 27(1):14–21.
   Google Scholar
• HALL CB, DOUGLAS RG JR, GEIMAN JM: Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J. Pediatr. (1976) 89(1):11–15.
   PubMed Web of Science ®Google Scholar
• DOMINGUEZ KD, MERCIER RC: Treatment of RSV pneumonia in adults-evidence of ribavirin effectiveness? Ann. Pharmacother. (1999) 33(6):739–741.
   Web of Science ®Google Scholar
• VUJOVIC O, MILLS J: Preventive and therapeutic strategies for respiratory syncytial virus infection. Curr. Opin. PharmacoL (2001) 1(5):497–503.
   PubMedGoogle Scholar
• WHIMBEY E, GHOSH S: Respiratory syncytial virus infections in immunocompromised adults. Curr. Clin. Top. Infect. Dis. (2000) 20:232–255.
   PubMedGoogle Scholar
• GREENOUGH A: Respiratory syncytial virus infection: clinical features, management, and prophylaxis. Curr. Opin. Pulm. Med. (2002) 8(3):214–217.
   PubMed Web of Science ®Google Scholar
• KIMPEN JL: Management of respiratory syncytial virus infection. Curr. Opin. Infect. Dis. (2001) 14(3):323–328.
   PubMed Web of Science ®Google Scholar
• EDELL D, KHOSHOO V, ROSS G, SALTER K: Early ribavarin treatment of bronchiolitis: effect on long-term respiratory morbidity. Chest (2002) 122(3):935–939.
   PubMed Web of Science ®Google Scholar
• GUERGUERIAN AM, GAUTHIER M, LEBEL MH, FARRELL CA, LACROIX J: Ribavirin in ventilated respiratory syncytial virus bronchiolitis. A randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. (1999) 160(3):829–834.
   PubMed Web of Science ®Google Scholar
• PATTERSON JL, FERNANDEZ-LARSSON R: Molecular mechanisms of action of ribavirin. Rev. Infect. Dis. (1990) 12(0:1139–1146.
   PubMedGoogle Scholar
• FERNANDEZ H, BANKS G, SMITH R: Ribavirin: a clinical overview. Eur. EpidemioL (1986) 2(1):1–14.
   PubMedGoogle Scholar
• SID WELL RW, ROBINS RK, HILLYARD IW: Ribavirin: an antiviral agent. PharmacoL Ther. (1979) 6(1):123–146.
   PubMedGoogle Scholar
• GROTTY S, MAAG D, ARNOLD JJ et aL: The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. (2000) 6(12):1375–1379.
   PubMed Web of Science ®Google Scholar
• ZHOU S, LIU R, BAROUDY BM, MALCOLM BA, REYES GR: The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology (2003) 310(2):333–342.
   PubMed Web of Science ®Google Scholar
• SEVERSON WE, SCHMALJOHN CS, JAVADIAN A, JONSSON CB: Ribavirin causes error catastrophe during Hantaan virus replication. J. ViroL (2003) 77(1):481–488.
   PubMed Web of Science ®Google Scholar
• GROTTY S, CAMERON CE, ANDINO R: RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. NatL Acad. Sci. USA (2001) 98(12):6895–6900.
   PubMed Web of Science ®Google Scholar
• MALLEY R, DEVINCENZO J, RAMILO O et aL: Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. (1998) 178(6):1555–1561.
   PubMed Web of Science ®Google Scholar
• ROECKL-WIEDMANN I, LIESE JG, GRILL E et aL: Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur. J. Pediatr. (2003) 162(4):237–244.
   PubMed Web of Science ®Google Scholar
• CASTANO-COLON AE, HULBERT BB, MAYER TK, WALSH EE, FALSEY AR: Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults. J. Clin. ViroL (2003) 28(2):169–174.
   PubMed Web of Science ®Google Scholar
• SLINGER R, MILK R, GABOURY I, DIAZ-MITOMA F: Evaluation of the QuickLab RSV test, a new rapid lateral-flow immunoassay for detection of respiratory syncytial virus antigen. J. Clin. MicrobioL (2004) 42(8):3731–3733.
   PubMed Web of Science ®Google Scholar
• DOUGLAS JL: In search of a small-molecule inhibitor for respiratory syncytial virus. Expert Rev. Anti Infect. Ther. (2004) 2(4):625–639.
   PubMedGoogle Scholar
• WYDE PR: Respiratory syncytial virus. In: Viral Infections and Treatment. Rtibsamen-Waigmann H (Ed.), Dekker, New York, USA (2003):91–138.
   Google Scholar
• MAGGON K: The ten billion dollar molecule. Pharm. Exec. (2003) 23:60–68.
   Google Scholar
• LAMBERT DM, BARNEY S, LAMBERT AL et al.: Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc. NatL Acad. Sci. USA (1996) 93(5):2186–2191.
   PubMed Web of Science ®Google Scholar
• MEANWELL NA, KRYSTAL M: Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents. Drug Discov. Today (2000) 5(6):241–252.
   PubMed Web of Science ®Google Scholar
• MCKIMM-BRESCHKIN J: VP-14637 ViroPharma. Curr. Opin. Investig: Drugs (2000) 1(4):425–427.
   PubMedGoogle Scholar
• WEISS WJ, MURPHY T, LYNCH ME et aL: Inhalation efficacy of RFT-641 in an African green monkey model of RSV infection. J. Med. PrimatoL (2003) 32(2):82–88.
   PubMed Web of Science ®Google Scholar
• RAZINKOV V HUNTLEY C, ELLESTAD G, KRISHNAIVIURTHY G: RSV entry inhibitors block F-protein mediated fusion with model membranes. Antiviral Res. (2002) 55(1):189–200.
   PubMed Web of Science ®Google Scholar
• HUNTLEY CC, WEISS WJ, GAZUMYAN A et ell.: RFT-641, a potent respiratory syncytial virus inhibitor. Antimicrob. Agents Chemother. (2002) 46(3):841–847.
   Google Scholar
• RAZINKOV V GAZUMYAN A, NIKITENKO A. ELLESTAD G, KRISHNAMURTHY G: RFT-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem. Biol. (2001) 8(7):645–659.
   PubMed Web of Science ®Google Scholar
• NIKITENKO AA, RATFELD YE, WANG TZ: The discovery of RFT-641 as a potent and selective inhibitor of the respiratory syncytial virus. Bioorg. Med. Chem. Lett. (2001) 11(8):1041–1044.
   PubMed Web of Science ®Google Scholar
• SUDO K, WATANABE W, KONNO K et aL: Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice. Antimicrob. Agents Chemother. (1999) 43(4):752–757.
   PubMed Web of Science ®Google Scholar
• SUDO K, YOSHIDA K, KONNO K et aL: Pharmacokinetics of a benzodithiin (RD3-0028) following aerosol treatment in rat. Xenobiotica (2002) 32(1):19–27.
   PubMed Web of Science ®Google Scholar
• SUDO K, KONNO K, WATANABE W, SHIGETA S, YOKOTA T: Mechanism of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028). MicrobioL Immunol. (2001) 45(7):531–537.
   PubMed Web of Science ®Google Scholar
• SUDO K, WATANABE W, MORI S et aL: Mouse model of respiratory syncytial virus infection to evaluate antiviral activity in vivo. Antiviral Chem. Chemother. (1999) 10(3):135–139.
   PubMed Web of Science ®Google Scholar
• WYDE PR, CHETTY SN, TIMMERMAN P, GILBERT BE, ANDRIES K: Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory Expert Opin. Biol. Ther (2005) 5(2) syncytial virus infection. Antiviral Res. (2003) 60(3):221–231.
   Google Scholar
• ANDRIES K, MOEREMANS M, GEVERS T et al.: Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res. (2003) 60(3):209–219.
   PubMed Web of Science ®Google Scholar
• CIANCI C, YU KL, COMBRINK K et al.: Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob. Agents Chemother. (2004) 48(2):413–422.
   PubMed Web of Science ®Google Scholar
• CIANCI C, GENOVESI EV, LAMB L et al.: Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob. Agents Chemother. (2004) 48(7):2448–2454.
   PubMed Web of Science ®Google Scholar
• CIANCI C, LANGLEY DR, DISCHINO DD et al.: Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion. Proc. Natl. Acad. Sci. USA (2004) 101(42):15046–15051.
   PubMed Web of Science ®Google Scholar
• WYDE PR, MOORE-POVEDA DK, DE CLERCQ E et al.: Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections. Antimicrob. Agents Chemother. (2000) 44(5):1146–1152.
   Google Scholar
• DE CLERCQ E, COOLS M, BALZARINI Jet al.: Antiviral activities of 5-ethyny1-1-beta-D-ribofitranosylimidazole-4- carboxamide and related compounds. Antimicrob. Agents Chemother. (1991) 35(4):679–684.
   Google Scholar
• WANG G, SAKTHIVEL K, RAJAPPAN V et al.: Synthesis of azole nucleoside 5'-monophosphate mimics (P1Ms) and their inhibitory properties of IMP dehydrogenases. Nucleosides Nucleotides Nucleic Acids (2004) 23(1-2):317–337.
   PubMed Web of Science ®Google Scholar
• WYDE PR, AMBROSE MW, MEYER HL, GILBERT BE: Toxicity and antiviral activity of LY253963 against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral. Res. (1990) 14(4-5):237–247.
   PubMed Web of Science ®Google Scholar
• JAIN J, ALMQUIST SJ, SHLYAKHTER D, HARDING MW: VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J. Pharm. Sci. (2001) 90(5):625–637.
   PubMed Web of Science ®Google Scholar
• MARKLAND W, MCQUAID TJ, JAIN J, KWONG AD: Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agents Chemother. (2000) 44(4):859–866.
   PubMed Web of Science ®Google Scholar
• HAYNES LM, TONKIN J, ANDERSON LJ, TRIPP RA: Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection. J. Wrol. (2002) 76(14):6873–6881.
   Google Scholar
• OTTOLINI MG, CURTIS SJ, PORTER DD et al.: Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats. Antimicrob. Agents Chemother. (2002) 46(7):2299–2302.
   PubMed Web of Science ®Google Scholar
• PRINCE GA, MATHEWS A, CURTIS SJ, PORTER DD: Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model with systemically administered monoclonal antibody (palivizumab) and glucocorticosteroid. J. Infect. Dis. (2000) 182:1326–1330.
   Web of Science ®Google Scholar
• GARRISON MM, CHRISTAKIS DA, HARVEY E, CUMMINGS P, DAVIS RL: Systemic corticosteroids in infant bronchiolitis: a meta-analysis. Pediatrics (2000) 105(4):E44.
   PubMedGoogle Scholar
• PATEL H, PLATT R, LOZANO JM, WANG EE: Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst. Rev. (2004) (3):CD004878.
   Google Scholar
• JOSEY AJ: The development of antiviral therapy and vaccines against respiratory syncytial virus and human parainfluenza virus type 3. Int. J. Pharmaceut. Med. (2001) 15:175-190. Detailed discussion on antiviral therapies in development, sorted by protein or process targeted.
   Google Scholar
• CHIN J, MAGOFFIN RL, SHEARER LA, SCHIEBLE JH, LENNETTE EH: Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. (1969) 89(4):449–463.
   PubMed Web of Science ®Google Scholar
• FULGINITI VA, ELLER JJ, SIEBER OF et al.: Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. (1969) 89(0435–448.
   Google Scholar
• KAPIKIAN AZ, MITCHELL RH, CHANOCK RM, SHVEDOFF RA, STEWART CE: An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. (1969) 89(4):405–421.
   PubMed Web of Science ®Google Scholar
• KIM HW, CANCHOLA JG, BRANDT CD et al.: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. (1969) 89(4):422–434.
   PubMed Web of Science ®Google Scholar
• DUDAS RA, KARRON RA: Respiratory syncytial virus vaccines. Clin. Microbiol. Rev. (1998) 11(3):430–439.
   PubMed Web of Science ®Google Scholar
• FIALL CB: Prospects for a respiratory syncytial virus vaccine. Science (1994) 265(5177):1393–1394.
   PubMed Web of Science ®Google Scholar
• HAYNES LM, JONES LP, BARSKEY A, ANDERSON LJ, TRIPP RA: Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. Virol. (2003) 77(18):9831–9844.
   Web of Science ®Google Scholar
• JAFRI HS: Role of chemokines in respiratory syncytial virus disease. Pediatr. Dis. J. (2002) 21(5):454–456.
   PubMed Web of Science ®Google Scholar
• VARGA SM, BRACIALE TJ: RSV-induced immunopathology: dynamic interplay between the virus and host immune response. Virology (2002) 295 (2):203–207.
   PubMed Web of Science ®Google Scholar
• HOLT PG, SLY PD: Interactions between RSV infection, asthma, and atopy: unraveling the complexities. J. Exp. Med. (2002) 196(10):1271–1275.
   PubMed Web of Science ®Google Scholar
• PRINCE Gk CURTIS SJ, YIM KC, PORTER DD: Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J. Gen. Virol. (2001) 82(Pt 12):2881–2888.
   PubMedGoogle Scholar
• OPENSHAW PJ, CULLEY FJ, OLSZEWSKA W: Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine (2001) 20\(Suppl. 1):527–531.
   Google Scholar
• MURPHY BR, COLLINS PL: Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J. Clin. Invest. (2002) 110(1):21–27.
   PubMed Web of Science ®Google Scholar
• KNEYBER MC, KIMPEN JL: Advances in respiratory syncytial virus vaccine development. Curr. Opin. Investig. Drugs (2004) 5(2):163–170.
   PubMedGoogle Scholar
• ZHANG L, PEEPLES ME, BOUCHER RC, COLLINS PL, PICKLES RJ: Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, andwithout obvious cytopathology. J. ViroL (2002) 76(11):5654–5666.
   PubMed Web of Science ®Google Scholar
• BANERJEE AK, BARIK S, DE BP: Gene expression of nonsegmented negative strand RNA viruses. Pharmacol. Ther. (1991) 51(1):47–70.
   PubMed Web of Science ®Google Scholar
• COLLINS PL, DICKENS LE, BUCKLER-WHITE A et al.: Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order. Proc. Natl. Acad. Sci. USA (1986) 83(13):4594–4598.
   PubMed Web of Science ®Google Scholar
• ZAMECNIK P: Background of the antisense oligonucleotide approach to chemotherapy. Antisense Nucleic Acid Drug Dev. (1997) 7(3):199–202.
   PubMedGoogle Scholar
• WU-PONG S, BYRON PR: Airway-to-biophase transfer of inhaled oligonucleotides. Adv. Drug Del. Rev. (1996) 19:47–71.
   Web of Science ®Google Scholar
• TEMPLIN MV, LEVIN AA, GRAHAM MJ et al.: Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice. Antisense Nucleic Acid Drug Dev. (2000) 10(5):359–368.
   PubMedGoogle Scholar
• NYCE JW, METZGER WJ: DNA antisense therapy for asthma in an animal model. Nature (1997) 385(6618):721–725.
   PubMed Web of Science ®Google Scholar
• DEAN NM, BENNETT CF: Antisense oligonucleotide-based therapeutics for cancer. Oncogene (2003) 22(50:9087-9096.
   Google Scholar
• PIROLLO KF, RAIT A, SLEER LS, CHANG EH: Antisense therapeutics: from theory to clinical practice. Pharmacol Ther. (2003) 99(1):55–77.
   PubMed Web of Science ®Google Scholar
• HOLMLUND JT: Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development. Ann. NY Acad. Sci. (2003) 1002:244–251.
   PubMed Web of Science ®Google Scholar
• CROOKE ST: Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol Toxicol (1992) 32:329–376.
   PubMed Web of Science ®Google Scholar
• CROOKE ST, GRAHAM MJ, ZUCKERMAN JE et al.: Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharm. Exp. Ther. (1996) 277(2):923–937.
   PubMed Web of Science ®Google Scholar
• KURRECK J: Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. (2003) 270(8):1628–1644.
   Google Scholar
• JAIRATH S, VARGAS PB, HAMLIN HA, FIELD AK, KILKUSKIE RE: Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Antiviral Res. (1997) 33(3):201–213.
   PubMed Web of Science ®Google Scholar
• BURGESS TL, FISHER EF, ROSS SL et al.: The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Nail. Acad. Sci. USA (1995) 92(9):4051–4055.
   PubMed Web of Science ®Google Scholar
• SIDDIQUI-JAIN A, GRAND CL, BEARSS DJ, HURLEY LH: Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc. Nail. Acad. Sci. USA (2002) 99(18):11593–11598.
   PubMed Web of Science ®Google Scholar
• VINORES SA: Technology evaluation: pegaptanib, Eyetech/Pfizer. Curr. Opin. Mol. Ther. (2003) 5(6):673–679.
   PubMed Web of Science ®Google Scholar
• EYETECH STUDY GROUP: Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology (2003) 110(5):979–986.
   PubMed Web of Science ®Google Scholar
• BITKO V BARIK S: Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC MicrobioL (2001) 1(1):34.
   PubMedGoogle Scholar
• BEHERA AK, MATSUSE H, KUMAR M et al.: Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection. Biochem. Biophys. Res. Commun. (2001) 280(1):188–195.
   PubMed Web of Science ®Google Scholar
• YU RZ, SU JQ, GRUNDY JS et al.: Prediction of clinical responses in a simulated Phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimens. Antisense Nucleic Acid Drug Dev. (2003) 13(1):57–66.
   PubMedGoogle Scholar
• FEFFERMAN DS, FARRELL RJ: Making sense of antisense: ISIS 2302 (alicaforsen) in the treatment of pouchitis. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchits. Inflamm. Bowel Dis. (2004) 10(4):487–488.
   Google Scholar
• MINER P, WEDEL M, BANE B, BRADLEY J: An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol. Ther. (2004) 19(3):281–286. YACYSHYN BR: Antisense oligonucleotide treatment of inflammatory bowel diseases. Methods MoL Med. (2004) 106:295-306. KAHAN BD, STEPKOWSKI S, KILIC M et al.: Phase I and Phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection. Transplantation (2004) 78(6):858–863. PLAYER MR, TORRENCE PF: The 2–5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol. Ther. (1998) 78(2):55–113. Comprehensive review of all aspects of 2-5A, including synthesis and properties of related 2',5'-linked ONs. SILVERMAN RH: Fascination with 2–5A-dependent RNase: a unique enzyme that functions in interferon action. J. Interferon Res. (1994) 14(3):101–104. STARK GR, KERR IM, WILLIAMS BR, SILVERMAN RH, SCHREIBER RD: How cells respond to interferons. Annu. Rev. Biochem. (1998) 67:227-264. Authoritative review on the mechanisms of IFN action.
   Google Scholar
• DONG B, XU L, ZHOU A et ell.: Intrinsic molecular activities of the interferon-induced 2-5A-dependent RNase. J. Biol. Chem. (1994) 269(19):14153–14158.
   Google Scholar
• TORRENCE PF, MAITRA RK, LESIAK K et al.: Targeting RNA for degradation with a (2'-5')oligoadenylate-antisense chimera. Proc. Natl Acad. Sci. USA (1993) 90(4):1300–1304.
   PubMed Web of Science ®Google Scholar
• PLAYER MR, BARNARD DL, TORRENCE PF: Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA. Proc. Natl Acad. Sci. USA (1998) 95(15):8874–8879.
   PubMed Web of Science ®Google Scholar
• •Description of 2-5A antisense targeting genomic RNA.
   Google Scholar
• BEHERA AK, KUMAR M, LOCKEY RF, MOHAPATRA SS: 2'-5' Oligoadenylate synthetase plays a critical role in interferon-gamma inhibition of respiratory syncytial virus infection of human epithelial cells. J. Biol Chem. (2002) 277(28):25601–25608.
   PubMed Web of Science ®Google Scholar
• CIRINO NM, LI G, MAO W, TORRENCE PF, SILVERMAN RH: Targeting RNA decay with 2',5' oligoadenylate-antisense in respiratory syncytial virus-infected cells. Proc. NatL Acad. Sci. USA (1997) 94(5):1937–1942.
   PubMed Web of Science ®Google Scholar
• •First description of inhibition of RSV by 2-5A antisense, including evidence of specific mRNA destruction.
   Google Scholar
• BARNARD DL, SIDWELL RW, XIAO W et al.: 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection. Antiviral Res. (1999) 41(3):119–134.
   PubMed Web of Science ®Google Scholar
• LEAMAN DW, LONGANO FJ, OKICKI JR et al.: Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense. Virology (2002) 292(1):70–77.
   PubMed Web of Science ®Google Scholar
• •First in vivo demonstration of the effectiveness of 2-5A antisense in treating RSV infections.
   Google Scholar
• SILVERMAN RH: In: Ribonucleases: Structure and Function. D'Alessio G, Riordan JF (Eds), Academic Press, New York, USA (1997):515–551.
   Google Scholar
• ••Comprehensive review of RNase L.
   Google Scholar
• TORRENCE PF, XIAO W, LI G et al.: Recruiting the 2-5A system for antisense therapeutics. Antisense Nucleic Acid Drug Dev. (1997) 7(3):203–206.
   PubMedGoogle Scholar
• MARAN A, MAITRA RK, KUMAR A et al.: Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science (1994) 265:789–792.
   PubMed Web of Science ®Google Scholar
• TORRENCE PF: 2-5A-antisense chimeras: inhibitors of respiratory syncytial virus infection. Curr. Opin. MoL Ther. (1999) 1(3):307–315.
   PubMed Web of Science ®Google Scholar
• ••Excellent review describing the strategy forselecting the intergenomic GS sequence and reasons for targeting RSV through the action of RNase L.
   Google Scholar
• TORRENCE PF, POWELL LD: The quest for an efficacious antiviral for respiratory syncytial virus. Antiviral Chem. Chemother. (2002) 13(6)025–344.
   Google Scholar
• ••Review describing ribavirin's mechanism ofaction, and the concept and possible future directions of targeting RSV with 2-5A antisense.
   Google Scholar
• XIANG Y, WANG Z, MURAKAMI J et al.: Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates. Cancer Res. (2003) 63(20):6795–6801.
   PubMed Web of Science ®Google Scholar
• TORRENCE PF, IMAI J, JOHNSTON MI: 5'-0- Monophosphoryladenyly1(2' goes to 5')adenyly1(2' goes to 5')adenosine is an antagonist of the action of 5'-0-triphosphoryladenyly142' goes to 5')adenyly1(2' goes to 5')adenosine and double-stranded RNA. Proc. Natl. Acad. Sci. USA (1981) 78(10):5993–5997.
   PubMed Web of Science ®Google Scholar
• JOHNSTON MI, TORRENCE PF: The role of interferon-induced proteins, double-stranded RNA, and 2',5'-oligoadenylate in the interferon-mediated inhibhition of viral translation. In: Interferon: Mechanisms of Production and Action. Friedman RM (Ed.), Elsevier Science, Amsterdam, The Netherlands (1984):189–298.
   Google Scholar
• TORRENCE PF: How interferon works. In: Biological Response Modifiers - New Approaches to Disease Intervention. Torrence PF (Ed.), Academic Press, New York, USA (1985):77–105.
   Google Scholar
• XU Z, KUANG M, OKICKI JR, CRAMER H, CHAUDHARY N: Potent inhibition of respiratory syncytial virus by combination treatment with 2-5A antisense and ribavirin. Antiviral Res. (2004) 61(3):195–206.
   PubMed Web of Science ®Google Scholar
• CRAMER H, OKICKI JR, KUANG M, XU Z: Targeted therapy of respiratory syncytial virus by 2-5A antisense. Nucleosides Nucleotides Nucleic Acids (2005) (Submitted).
   Google Scholar
• WYDE PR, AMBROSE MW, MEYER HL, ZOLINSKI CL, GILBERT BE: Evaluation of the toxicity and antiviral activity of carbocyclic 3-deazaadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral Res. (1990) 14(4-5):215–225.
   PubMed Web of Science ®Google Scholar
• KNIGHT V, GILBERT BE, WYDE PR, ENGLUND JA: High dose-short duration ribavirin aerosol treatment-a review. Bull. Int. Union Tuberc. Lung Dis. (1991) 66(2-3) :97–101.
   PubMedGoogle Scholar
• GILBERT BE, WYDE PR, AMBROSE MW, WILSON SZ, KNIGHT V: Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats. Antiviral Res. (1992) 17(1):33–42.
   PubMed Web of Science ®Google Scholar
• GILBERT BE, KNIGHT V: Biochemistry and clinical applications of ribavirin. Antimicrob. Agents Chemother. (1986) 30(2):201–205.
   PubMed Web of Science ®Google Scholar
• WYDE PR, WILSON SZ, PETRELLA R, GILBERT BE: Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice. Antiviral Res. (1987) 7(4):211–220.
   PubMed Web of Science ®Google Scholar